John Boyce, Co-Founder, President and CEO of GnuBIO Named by Mass High Tech and the Boston Business Journal as one of the 2012 Innovation All-Stars

Cambridge, MA (October 1, 2012): GnuBIO announced today that its Co-Founder, President & CEO, John Boyce, has been named a Technology Luminary as part of the 2012 Innovation All-Stars Awards selected by Mass High Tech (MHT) and the Boston Business Journal (BBJ).  As part of a partnership between the sister publications, Technology Luminaries from across various industries who contribute to the innovation economy of Massachusetts were nominated by readers.  John Boyce was one of fifteen Technology Luminaries. MHT also selected 15 Rising Stars who are building next generation companies within their respective industries.

“As you can imagine, we are very proud that John Boyce, President and CEO of GnuBIO, has been recognized for his life-long work in the life sciences industry,” said David Weitz, Mallinckrodt Professor of Physics & Applied Physics at Harvard University, and a member of the National Academy of Sciences.  “Our company’s goal is to commercialize the leading desktop sequencing system – a new technology suitable for clinical care and diagnostics as well as research laboratories of all sizes, large and small.  John Boyce is the visionary who is leading this game-changing technology,” Weitz continued.

Chris McIntosh, publisher of the Boston Business Journal and Mass High Tech stated, “MHT’s 15 Tech Luminaries choices reflect deep accomplishment in various technology-related industries. “  “…it’s a potent combination of 30 notable and potent players in the local economy, and we hope your success will inspire others to innovate, which is the main driving force of the local economy.”

“The Technology Luminary award is a testament to John Boyce’s successful track record commercializing disruptive technologies,” states Susie Harborth, senior vice president at GnuBIO. “John has spent his entire career building high-impact life science companies and GnuBIO is one example of his extraordinary ability to translate ideas into products, while changing the healthcare landscape for patients around the world,” Harborth continued.

The Award Recipients will be honored with a celebration and networking reception on Wednesday, Nov. 14 at the House of Blues in Boston.

About GnuBIO:  GnuBIO is a privately-held company developing next-generation desktop DNA sequencing technology that will compartmentalize the entire DNA sequencing process, combining all of the steps required for sequencing in a single system, and providing the only fully integrated next-generation sequencing workflow. The GnuBIO sequencing technology is based on an emulsion based microfluidic technology which also provides a scalable sequencing solution that allows for interrogation of single genes, gene panels or whole genomes. The user of his GnuBIO system simply injects the patient sample into the GnuBIO cartridge, the appropriate panel is run – inclusive of gene capture, PCR, sequencing, and informatics analysis – and the results are ready within hours.  Unlike any other DNA sequencing system, the entire process is all on the chip, simplifying the complex sample preparation process and breaking the barrier of an obstacle that has prevented the widespread adoption of DNA sequencing.

GnuBIO, Inc.
Jessica Tonani

[email protected]



One Kendall Square

Building 1400, 2nd Floor

Cambridge, MA 02139